TransThera Sciences (Nanjing), Inc. released its first Environmental, Social and Governance Report, covering operations from 1 January to 31 December 2025 and focusing on headquarters, R&D centre and Nanjing offices.

R&D AND PIPELINE • Core product Tinengotinib, a multi-target small-molecule kinase inhibitor, progressed to New Drug Application stage on 19 December 2025 for FGFR inhibitor-resistant cholangiocarcinoma after inclusion in China’s priority review list. • The portfolio totals seven clinical and one pre-clinical candidates across oncology, inflammatory and cardiometabolic indications. • A royalty-bearing collaboration with Neurocrine Biosciences on NLRP3 inhibitors could deliver up to US$881.50 million. • Strategic cooperation with Akeso advances combination trials of Tinengotinib with cadonilimab and ivonescimab for advanced hepatocellular carcinoma.

GOVERNANCE AND COMPLIANCE • A seven-member Board oversees ESG strategy via an ESG working group and modern committee structure. • No corruption or bribery cases were identified in 2025; comprehensive anti-corruption and IP compliance systems are in place.

ENVIRONMENTAL PERFORMANCE (2025) • Total greenhouse-gas emissions: 728.89 tonnes (Scope 1: 0; Scope 2: 728.89); intensity: 5.93 t per employee. • Scope 3 emissions reported at 71.77 tonnes. • Hazardous waste: 18.27 tonnes; non-hazardous waste: 0.86 tonnes. • Wastewater: 3,497 tonnes; all discharge parameters within regulatory limits. • Energy use: 1.04 million kWh (electricity only); water consumption per employee: 28.43 t. • Climate strategy incorporates Board-level oversight, scenario analysis and emergency plans for extreme weather.

SOCIAL INDICATORS • Workforce: 123 employees; 63 % female; turnover rate: 1.6 %. • Training coverage: 100 %; average 17.72 hours per employee. • Zero work-related fatalities or lost days; dedicated PPE and emergency-drill programmes conducted. • Supplier base: 239 domestic and 25 overseas partners subject to integrity and ESG audits.

COMMUNITY ENGAGEMENT • Continued support for the “A Book Corner in Every Classroom” project (2021-2023), donating quality reading materials to rural schools in Guizhou.

HONOURS • Recognitions include Deloitte “China Medical and Health Rising Star”, “Jiangsu Provincial Potential Unicorn Enterprise” and designation as a foreign-funded R&D centre in Nanjing.

The report aligns with Hong Kong Stock Exchange ESG Reporting Guide requirements and underscores TransThera’s commitment to sustainable practices while advancing innovative therapeutics.